<table id="table5" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 5	Effect of Saquinavir (+/- Ritonavir) on the Pharmacokinetics of Coadministered Drugs</caption>
<col align="left" valign="top" width="36%"></col>
<col align="left" valign="top" width="25%"></col>
<col align="center" valign="top" width="5%"></col>
<col align="center" valign="top" width="17%"></col>
<col align="center" valign="top" width="17%"></col>
<thead>
<tr>
<th stylecode="Lrule Rrule">Coadministered Drug</th>
<th align="center" stylecode="Rrule">Saquinavir soft gel capsules  or saquinavir soft gel capsules/<br/>ritonavir</th>
<th stylecode="Rrule">N</th>
<th colspan="2" stylecode="Rrule Botrule">% Change for Coadministered Drug</th>
</tr>
<tr stylecode="Botrule">
<th stylecode="Lrule Rrule"></th>
<th align="center" stylecode="Rrule">Dose</th>
<th stylecode="Rrule"></th>
<th stylecode="Rrule">AUC (95% CI)</th>
<th stylecode="Rrule">C<sub>max</sub> (95% CI)</th>
</tr>
</thead>
<tfoot>
<tr>
<td align="left" colspan="5">↑ Denotes an average increase in exposure by the percentage indicated.</td>
</tr>
<tr>
<td align="left" colspan="5">↓ Denotes an average decrease in exposure by the percentage indicated.</td>
</tr>
<tr>
<td align="left" colspan="5">↔ Denotes no statistically significant change in exposure was observed.</td>
</tr>
<tr>
<td align="left" colspan="5">S Subjects</td>
</tr>
<tr>
<td align="left" colspan="5">V Healthy Volunteers</td>
</tr>
<tr>
<td align="left" colspan="5">M Methadone-dependent, HIV negative subjects</td>
</tr>
<tr>
<td align="left" colspan="5">NA	Not Available </td>
</tr>
</tfoot>
<tbody>
<tr>
<td stylecode="Lrule Rrule Toprule">Clarithromycin 500 mg bid × 7 days<br/>  Clarithromycin<br/>  14-OH clarithromycin metabolite</td>
<td stylecode="Rrule Toprule">1200 mg tid × 7 days</td>
<td stylecode="Rrule Toprule">12V</td>
<td stylecode="Rrule Toprule">↑45% (17-81%)<br/>↓24% (5-40%)</td>
<td stylecode="Rrule Toprule">↑39% (10-76%)<br/>↓34% (14-50%)</td>
</tr>
<tr>
<td stylecode="Lrule Rrule Toprule">Enfuvirtide 90 mg SC q12h (bid) for 7 days</td>
<td stylecode="Rrule Toprule">1000/100 mg bid</td>
<td stylecode="Rrule Toprule Botrule">12S</td>
<td stylecode="Rrule Toprule">↔</td>
<td stylecode="Rrule Toprule Botrule">↔</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule Toprule">Sildenafil 100-mg single dose</td>
<td stylecode="Rrule Toprule">1200 mg tid × 8 days</td>
<td stylecode="Rrule">27V</td>
<td stylecode="Rrule Toprule">↑210% (150-300%)</td>
<td stylecode="Rrule">↑140% (80-230%)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Efavirenz 600 mg qd</td>
<td stylecode="Rrule">1200 mg tid</td>
<td stylecode="Rrule">13V</td>
<td stylecode="Rrule">↓12%</td>
<td stylecode="Rrule">↓13%</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule"></td>
<td align="center" stylecode="Rrule">
<content stylecode="bold">INVIRASE/ritonavir<br/>Dose</content>
</td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule"></td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Digoxin 0.5 mg single dose</td>
<td stylecode="Rrule">1000/100 mg bid × 16 days</td>
<td stylecode="Rrule">16V</td>
<td stylecode="Rrule">↑49% (32-69%)<footnote id="tb5ft4">90% Confidence Interval </footnote>
</td>
<td stylecode="Rrule">↑27% (5-54%)<footnoteref idref="tb5ft4"></footnoteref>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">R-Methadone 60-120 mg qd</td>
<td stylecode="Rrule">1000/100 mg bid × 14 days</td>
<td stylecode="Rrule">12M</td>
<td stylecode="Rrule">↓19% (9-29%)<footnoteref idref="tb5ft4"></footnoteref>
</td>
<td stylecode="Rrule">NA</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Ketoconazole 200 mg/day</td>
<td stylecode="Rrule">1000/100 mg bid</td>
<td stylecode="Rrule">12V</td>
<td stylecode="Rrule">↑168% (146-193%)<footnoteref idref="tb5ft4"></footnoteref>
</td>
<td stylecode="Rrule">↑45% (32-59%)<footnoteref idref="tb5ft4"></footnoteref>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Midazolam 7.5 mg oral single dose</td>
<td stylecode="Rrule">1000/100 mg bid</td>
<td stylecode="Rrule">16V</td>
<td stylecode="Rrule">↑1144% (975-1339%)<footnoteref idref="tb5ft4"></footnoteref>
</td>
<td stylecode="Rrule">↑327% (264 -402%)<footnoteref idref="tb5ft4"></footnoteref>
</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Rifabutin 150 mg q4d</td>
<td stylecode="Rrule">1000/100 mg bid</td>
<td stylecode="Rrule">11V</td>
<td stylecode="Rrule">↑60%<footnote id="tb5ft1">AUC<sub>0-96hr</sub> and C<sub>max</sub> of the active moiety (rifabutin + 25-O-desacetyl rifabutin)</footnote>
<footnote id="tb5ft2">Compared to rifabutin 150 mg QD </footnote>
<br/>(43-79%)<footnoteref idref="tb5ft4"></footnoteref>
<br/>↔<footnote id="tb5ft3">AUC<sub>0-96hr</sub> and C<sub>max</sub> for rifabutin only</footnote> (-10 to 13%)<footnoteref idref="tb5ft4"></footnoteref>
</td>
<td stylecode="Rrule">↑111%<footnoteref idref="tb5ft1"></footnoteref>
<footnoteref idref="tb5ft2"></footnoteref>
<br/>(75-153%)<footnoteref idref="tb5ft4"></footnoteref>
<br/>↑68%<footnoteref idref="tb5ft3"></footnoteref> (38-105%)<footnoteref idref="tb5ft4"></footnoteref>
</td>
</tr>
</tbody>
</table>